Skip to content

5401 S. Congress Ave, Ste 201 Atlantis, FL 33462

(561)995-6971

(561)569-8309

Pay Bills

Home
Meet The Team
Conditions We Treat
Services
Resources
Contact Us

Home
Meet The Team
Conditions We Treat
Services
Resources
Contact Us

Category: us

Search

Antibodies Remain 6 Months After Chikungunya Vaccine Administered in Youngest Children

Today, Valneva announced results from its phase 2 clinical trial, which demonstrated positive 6-month antibody

June 5, 2025 No Comments

First Participant Enrolled in Phase 2 Study for Investigational Antifungal For Cryptococcal Meningitis

Mycovia Pharmaceuticals is evaluating oteseconazole against the standard of care for treating cryptococcal meningitis. Source

June 5, 2025 No Comments

Ceftolozane/Tazobactam Shows Strong Activity Against ESBL E coli, But Gaps Remain for K pneumoniae

A recent study presented by Taylor Hein, MLS, at the 2025 MAD-ID Meeting explored the

June 5, 2025 No Comments

Vancomycin Loading Doses Improve Target Timing and Safety in 61,000+ Cases

A large real-world retrospective cohort study presented at MAD-ID 2025 by Tiffany Lee, PharmD, an

June 5, 2025 No Comments

No Significant Difference Between Doxycycline and Minocycline for Bone and Joint Infections

A multi-hospital retrospective cohort study conducted across Indiana University Health (IU Health) hospitals has found

June 4, 2025 No Comments

Immunocompromised Patients on OPAT Face Nearly Double the Risk of 30-Day Readmission

A retrospective study presented at MAD-ID 2025 suggests that immunocompromised (IC) patients receiving outpatient parenteral

June 4, 2025 No Comments

Gyre Therapeutics’ Hydronidone Meets Primary Endpoint in Phase 3 Hepatitis B Trial

Lungen Lu, MD Image Credit: Hepatology Digest on LinkedIn Hydronidone met the primary endpoint in

June 4, 2025 No Comments

Long-Acting, Off-Label Alternative for Serious Bacterial Infections

David Goodman-Meza, MD, PhD The long-acting lipoglycopeptides (laLGPs) dalbavancin and oritavancin, currently indicated for skin

June 3, 2025 No Comments

VOWST Maintains Consistent Safety Profile in rCDI Patients with Comorbidities

At the 2025 MAD-ID meeting, Dianne Nguyen, MD, head of medical affairs for the pharmaceutical

June 3, 2025 No Comments

Reviewing the Efficacy and Safety of Omadacycline in Immunocompromised Patients

In a new study presented at MAD-ID, omadacycline was found to have an 86% clinical

June 3, 2025 No Comments

Schedule an Appointment

Quick Links

Home
Meet The Team
Services
Resources
Contact Us

Patient Forms

Consent Form
Notice of Privacy Practices
Patient Info
Intake Form
Insurance Information

Contact Us

Monday - Friday : 09:00 AM - 04:30 PM
5401 S. Congress Ave, Ste 201 Atlantis, FL 33462

Copyright © 2024 atlasidp.

Privacy Policy
Terms & Condition

Home
Meet The Team
Conditions We Treat
Services
Resources
Contact Us